Premium
Oral tofacitinib for psoriasis: what happens with interrupted treatment?
Author(s) -
Alinia H.,
Feldman S.R.
Publication year - 2015
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13766
Subject(s) - tofacitinib , medicine , janus kinase inhibitor , discontinuation , psoriasis , dermatology , dosing , psoriasis area and severity index , etanercept , randomized controlled trial , pharmacology , rheumatoid arthritis
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom